Zacks: Brokerages Expect Voyager Therapeutics Inc (VYGR) Will Announce Earnings of -$0.83 Per Share

Share on StockTwits

Wall Street analysts expect that Voyager Therapeutics Inc (NASDAQ:VYGR) will post ($0.83) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Voyager Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.70) and the lowest estimate coming in at ($0.97). Voyager Therapeutics reported earnings of ($0.80) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 3.7%. The business is expected to report its next earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that Voyager Therapeutics will report full-year earnings of ($2.92) per share for the current year, with EPS estimates ranging from ($3.92) to ($1.30). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.77) per share, with EPS estimates ranging from ($3.86) to ($1.60). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Voyager Therapeutics.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Tuesday, May 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.65 by ($1.46). Voyager Therapeutics had a negative net margin of 804.55% and a negative return on equity of 129.67%. The company had revenue of $5.20 million during the quarter, compared to analysts’ expectations of $3.00 million.

A number of research firms have recently commented on VYGR. ValuEngine downgraded Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, February 4th. Zacks Investment Research downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 2nd. HC Wainwright restated a “buy” rating and set a $22.00 price objective on shares of Voyager Therapeutics in a report on Monday, May 6th. BidaskClub upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, May 8th. Finally, Cantor Fitzgerald began coverage on Voyager Therapeutics in a report on Tuesday, March 5th. They set an “overweight” rating and a $27.00 price objective for the company. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $24.11.

In related news, major shareholder Neurocrine Biosciences Inc purchased 4,179,728 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was purchased at an average cost of $11.96 per share, for a total transaction of $49,989,546.88. Following the acquisition, the insider now owns 4,179,728 shares in the company, valued at $49,989,546.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 33.60% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG3 Management LLC acquired a new stake in Voyager Therapeutics in the 1st quarter valued at $57,000. BNP Paribas Arbitrage SA increased its holdings in Voyager Therapeutics by 74,766.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,492 shares of the company’s stock valued at $86,000 after purchasing an additional 4,486 shares in the last quarter. Macquarie Group Ltd. increased its holdings in Voyager Therapeutics by 1,800.0% in the 1st quarter. Macquarie Group Ltd. now owns 5,700 shares of the company’s stock valued at $109,000 after purchasing an additional 5,400 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its holdings in Voyager Therapeutics by 449.4% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock valued at $85,000 after purchasing an additional 7,401 shares in the last quarter. Finally, Bank of America Corp DE increased its holdings in Voyager Therapeutics by 211.0% in the 4th quarter. Bank of America Corp DE now owns 10,637 shares of the company’s stock valued at $100,000 after purchasing an additional 7,217 shares in the last quarter. Hedge funds and other institutional investors own 74.46% of the company’s stock.

Shares of VYGR stock traded up $1.27 on Friday, reaching $24.12. 268,094 shares of the stock were exchanged, compared to its average volume of 503,092. The company has a market cap of $888.39 million, a price-to-earnings ratio of -8.77 and a beta of 2.82. Voyager Therapeutics has a 1-year low of $7.76 and a 1-year high of $25.74.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

Read More: Are all No-Load Funds Equal?

Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Barry Zwarenstein Sells 7,663 Shares of Five9 Inc  Stock
Barry Zwarenstein Sells 7,663 Shares of Five9 Inc Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc  Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc Stock
Insider Selling: Neogen Co.  Director Sells 5,000 Shares of Stock
Insider Selling: Neogen Co. Director Sells 5,000 Shares of Stock
Neogen Co.  Director Sells $314,650.00 in Stock
Neogen Co. Director Sells $314,650.00 in Stock
Insider Selling: Airgain Inc  CEO Sells 22,464 Shares of Stock
Insider Selling: Airgain Inc CEO Sells 22,464 Shares of Stock
Insider Selling: Bottomline Technologies  Insider Sells 9,925 Shares of Stock
Insider Selling: Bottomline Technologies Insider Sells 9,925 Shares of Stock


© 2006-2019 Ticker Report